IMPACT BIOMEDICAL INC (IBO) Fundamental Analysis & Valuation

NYSEARCA:IBO • US45259L2051

0.5588 USD
+0.01 (+1.6%)
Last: Mar 12, 2026, 03:56 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This IBO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

0

Overall IBO gets a fundamental rating of 0 out of 10. We evaluated IBO against 193 industry peers in the Pharmaceuticals industry. IBO may be in some trouble as it scores bad on both profitability and health. IBO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. IBO Profitability Analysis

1.1 Basic Checks

  • In the past year IBO has reported negative net income.
  • In the past year IBO has reported a negative cash flow from operations.
IBO Yearly Net Income VS EBIT VS OCF VS FCFIBO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • The Return On Assets of IBO (-201.86%) is worse than 87.56% of its industry peers.
Industry RankSector Rank
ROA -201.86%
ROE N/A
ROIC N/A
ROA(3y)-48.88%
ROA(5y)N/A
ROE(3y)-207.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBO Yearly ROA, ROE, ROICIBO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

  • IBO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBO Yearly Profit, Operating, Gross MarginsIBO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -5K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. IBO Health Analysis

2.1 Basic Checks

  • IBO has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, IBO has a worse debt to assets ratio.
IBO Yearly Shares OutstandingIBO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M 8M 10M
IBO Yearly Total Debt VS Total AssetsIBO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • IBO has an Altman-Z score of -4.83. This is a bad value and indicates that IBO is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of IBO (-4.83) is worse than 61.66% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.83
ROIC/WACCN/A
WACCN/A
IBO Yearly LT Debt VS Equity VS FCFIBO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 0.06 indicates that IBO may have some problems paying its short term obligations.
  • IBO's Current ratio of 0.06 is on the low side compared to the rest of the industry. IBO is outperformed by 94.82% of its industry peers.
  • A Quick Ratio of 0.04 indicates that IBO may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.04, IBO is doing worse than 94.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.04
IBO Yearly Current Assets VS Current LiabilitesIBO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. IBO Growth Analysis

3.1 Past

  • IBO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -509.26%.
EPS 1Y (TTM)-509.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1423.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IBO Yearly Revenue VS EstimatesIBO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 10K 20K 30K 40K

More info and screens

Find the best growth stocksShow best growing peers

0

4. IBO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IBO. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBO Price Earnings VS Forward Price EarningsIBO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBO Per share dataIBO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IBO Dividend Analysis

5.1 Amount

  • No dividends for IBO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IBO Fundamentals: All Metrics, Ratios and Statistics

IMPACT BIOMEDICAL INC

NYSEARCA:IBO (3/12/2026, 3:56:24 PM)

0.5588

+0.01 (+1.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners1.38%
Inst Owner Change166.04%
Ins Owners0.43%
Ins Owner Change0%
Market Cap58.46M
Revenue(TTM)7.00K
Net Income(TTM)-38.47M
AnalystsN/A
Price TargetN/A
Short Float %1.26%
Short Ratio1.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8351.67
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.58
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0
BVpS-0.1
TBVpS-0.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -201.86%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.88%
ROA(5y)N/A
ROE(3y)-207.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.04
Altman-Z -4.83
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-509.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1423.03%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-36.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.46%
OCF growth 3YN/A
OCF growth 5YN/A

IMPACT BIOMEDICAL INC / IBO FAQ

What is the ChartMill fundamental rating of IMPACT BIOMEDICAL INC (IBO) stock?

ChartMill assigns a fundamental rating of 0 / 10 to IBO.


What is the valuation status for IBO stock?

ChartMill assigns a valuation rating of 0 / 10 to IMPACT BIOMEDICAL INC (IBO). This can be considered as Overvalued.


What is the profitability of IBO stock?

IMPACT BIOMEDICAL INC (IBO) has a profitability rating of 0 / 10.